First Trust Advisors
PCVX icon

First Trust Advisors’s Vaxcyte PCVX Stock Holding History

First Trust Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-123,568
Closed -$10.1M – 2600
2024
Q4 		$10.1M Buy
123,568
+5,704
+5% +$566K 0.01% 1053
2024
Q3 		$13.5M Buy
117,864
+38,938
+49% +$3.51M 0.01% 946
2024
Q2 		$5.96M Buy
78,926
+15,100
+24% +$1.03M 0.01% 1193
2024
Q1 		$4.36M Sell
63,826
-13,810
-18% -$956K ﹤0.01% 1370
2023
Q4 		$4.88M Buy
77,636
+44,923
+137% +$2.33M 0.01% 1277
2023
Q3 		$1.67M Sell
32,713
-2,691
-8% -$133K ﹤0.01% 1758
2023
Q2 		$1.77M Sell
35,404
-1,806
-5% -$85.6K ﹤0.01% 1777
2023
Q1 		$1.39M Buy
37,210
+16,749
+82% +$710K ﹤0.01% 1851
2022
Q4 		$981K Buy
+20,461
New +$803K ﹤0.01% 1967

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

First Trust Advisors's PCVX Position: Q1 2025 in Review

First Trust Advisors sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 123,568 shares — an estimated $10.1M sold.

First Trust Advisors first reported a position in PCVX in Q4 2022 and held it in 9 quarters. The position peaked at $13.5M in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • First Trust Advisors reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • First Trust Advisors sold 123,568 Vaxcyte shares in Q1 2025, an estimated $10.1M.
  • First Trust Advisors first reported a position in Vaxcyte in Q4 2022 and held it in 9 quarters.
  • First Trust Advisors's Vaxcyte position peaked at $13.5M in Q3 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on First Trust Advisors's 13F filing for Q1 2025, filed 14 May 2025.